\
&
Contact us
Published on | 3 months ago
ProgrammesThe SME Market Expansion Open Call 2026 seeks to boost the market uptake of impactful innovations while mitigating development risks. With a total funding pool of €600,000, the initiative plans to support around 10 projects, each awarded €60,000. Interested small and medium enterprises (SMEs) must engage with an end-client, a public or private entity, to validate their solutions in real-world scenarios. The Call prioritises five thematic areas including Public Transport and Urban Logistics and excludes SMEs funded in the previous 2025 call.
Applications are open until 1 December 2025. For further information on the application procedure, you can visit this website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
The EU introduced a new ICT Supply Chain Security Toolbox, providing an EU approach to identify, assess, and mitigate cybersecurity risks across ICT supply chains. The toolbox will help Member States and public and private actors to bolster the security of ICT supply chains in the EU as set out in the revised Cybersecurity Act presented... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.